| Aparna R Kakarala, MD | |
|
1200 Everett Dr, 1np606, Oklahoma City, OK 73104-5047 | |
| (405) 271-5125 | |
| Not Available |
| Full Name | Aparna R Kakarala |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 27 Years |
| Location | 1200 Everett Dr, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801864186 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 057672 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Emory University Hospital | Atlanta, GA | Hospital |
| Grady Memorial Hospital | Atlanta, GA | Hospital |
| Emory University Hospital Midtown | Atlanta, GA | Hospital |
| Emory Decatur Hospital | Decatur, GA | Hospital |
| Saint Joseph's Hospital Of Atlanta, Inc | Atlanta, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emory Medical Care Foundation Inc | 4981501814 | 801 |
| The Emory Clinic, Inc | 8820901408 | 2687 |
News Archive
Most makers of approved drug and biological products are meeting their regulatory obligations and meeting targets for postmarketing studies/clinical trials in a timely manner, according to a study released today by the U.S. Food and Drug Administration (FDA).
Covidien plc today reported results for the second quarter of fiscal 2011 (January - March 2011). Net sales of $2.80 billion increased 10% from the $2.55 billion reported in the second quarter a year ago. Foreign exchange rate movement added approximately two percentage points to the quarterly sales growth rate.
Until recently, only one of the approximately 30,000 genes in the human genome has been linked to risk of late-onset Alzheimer's disease (AD).
Blueprint Medicines today announced the completion of a $25 million Series B financing. The oncology-focused investor, Nextech Invest Ltd., led the round, which also included founding investors Third Rock Ventures and Fidelity Biosciences as well as public investors Biotech Value Fund, L.P., Casdin Capital, LLC and other undisclosed investors.
› Verified 8 days ago
| Entity Name | The Emory Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396798229 PECOS PAC ID: 8820901408 Enrollment ID: O20031110000503 |
News Archive
Most makers of approved drug and biological products are meeting their regulatory obligations and meeting targets for postmarketing studies/clinical trials in a timely manner, according to a study released today by the U.S. Food and Drug Administration (FDA).
Covidien plc today reported results for the second quarter of fiscal 2011 (January - March 2011). Net sales of $2.80 billion increased 10% from the $2.55 billion reported in the second quarter a year ago. Foreign exchange rate movement added approximately two percentage points to the quarterly sales growth rate.
Until recently, only one of the approximately 30,000 genes in the human genome has been linked to risk of late-onset Alzheimer's disease (AD).
Blueprint Medicines today announced the completion of a $25 million Series B financing. The oncology-focused investor, Nextech Invest Ltd., led the round, which also included founding investors Third Rock Ventures and Fidelity Biosciences as well as public investors Biotech Value Fund, L.P., Casdin Capital, LLC and other undisclosed investors.
› Verified 8 days ago
| Entity Name | Emory Medical Care Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063452381 PECOS PAC ID: 4981501814 Enrollment ID: O20031217000968 |
News Archive
Most makers of approved drug and biological products are meeting their regulatory obligations and meeting targets for postmarketing studies/clinical trials in a timely manner, according to a study released today by the U.S. Food and Drug Administration (FDA).
Covidien plc today reported results for the second quarter of fiscal 2011 (January - March 2011). Net sales of $2.80 billion increased 10% from the $2.55 billion reported in the second quarter a year ago. Foreign exchange rate movement added approximately two percentage points to the quarterly sales growth rate.
Until recently, only one of the approximately 30,000 genes in the human genome has been linked to risk of late-onset Alzheimer's disease (AD).
Blueprint Medicines today announced the completion of a $25 million Series B financing. The oncology-focused investor, Nextech Invest Ltd., led the round, which also included founding investors Third Rock Ventures and Fidelity Biosciences as well as public investors Biotech Value Fund, L.P., Casdin Capital, LLC and other undisclosed investors.
› Verified 8 days ago
| Entity Name | Emory Specialty Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407864168 PECOS PAC ID: 3476559782 Enrollment ID: O20061010000447 |
News Archive
Most makers of approved drug and biological products are meeting their regulatory obligations and meeting targets for postmarketing studies/clinical trials in a timely manner, according to a study released today by the U.S. Food and Drug Administration (FDA).
Covidien plc today reported results for the second quarter of fiscal 2011 (January - March 2011). Net sales of $2.80 billion increased 10% from the $2.55 billion reported in the second quarter a year ago. Foreign exchange rate movement added approximately two percentage points to the quarterly sales growth rate.
Until recently, only one of the approximately 30,000 genes in the human genome has been linked to risk of late-onset Alzheimer's disease (AD).
Blueprint Medicines today announced the completion of a $25 million Series B financing. The oncology-focused investor, Nextech Invest Ltd., led the round, which also included founding investors Third Rock Ventures and Fidelity Biosciences as well as public investors Biotech Value Fund, L.P., Casdin Capital, LLC and other undisclosed investors.
› Verified 8 days ago
| Entity Name | Grady Memorial Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649765686 PECOS PAC ID: 7517032998 Enrollment ID: O20181107003377 |
News Archive
Most makers of approved drug and biological products are meeting their regulatory obligations and meeting targets for postmarketing studies/clinical trials in a timely manner, according to a study released today by the U.S. Food and Drug Administration (FDA).
Covidien plc today reported results for the second quarter of fiscal 2011 (January - March 2011). Net sales of $2.80 billion increased 10% from the $2.55 billion reported in the second quarter a year ago. Foreign exchange rate movement added approximately two percentage points to the quarterly sales growth rate.
Until recently, only one of the approximately 30,000 genes in the human genome has been linked to risk of late-onset Alzheimer's disease (AD).
Blueprint Medicines today announced the completion of a $25 million Series B financing. The oncology-focused investor, Nextech Invest Ltd., led the round, which also included founding investors Third Rock Ventures and Fidelity Biosciences as well as public investors Biotech Value Fund, L.P., Casdin Capital, LLC and other undisclosed investors.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Aparna R Kakarala, MD 1183 Dunwoody Village Dr, Atlanta, GA 30338-2323 Ph: (770) 393-9559 | Aparna R Kakarala, MD 1200 Everett Dr, 1np606, Oklahoma City, OK 73104-5047 Ph: (405) 271-5125 |
News Archive
Most makers of approved drug and biological products are meeting their regulatory obligations and meeting targets for postmarketing studies/clinical trials in a timely manner, according to a study released today by the U.S. Food and Drug Administration (FDA).
Covidien plc today reported results for the second quarter of fiscal 2011 (January - March 2011). Net sales of $2.80 billion increased 10% from the $2.55 billion reported in the second quarter a year ago. Foreign exchange rate movement added approximately two percentage points to the quarterly sales growth rate.
Until recently, only one of the approximately 30,000 genes in the human genome has been linked to risk of late-onset Alzheimer's disease (AD).
Blueprint Medicines today announced the completion of a $25 million Series B financing. The oncology-focused investor, Nextech Invest Ltd., led the round, which also included founding investors Third Rock Ventures and Fidelity Biosciences as well as public investors Biotech Value Fund, L.P., Casdin Capital, LLC and other undisclosed investors.
› Verified 8 days ago
Dr. Jennifer Kathleen Hinkle, MD Radiology Medicare: Medicare Enrolled Practice Location: 921 Ne 13th St, Oklahoma City, OK 73104 Phone: 405-456-2589 | |
Dr. Bryan Lee Vanzandt, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 4625 S Western Ave, Oklahoma City, OK 73109 Phone: 405-632-2323 Fax: 405-631-9315 | |
Charles Eric Eckman, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 14101 Parkway Commons, Oklahoma City, OK 73134 Phone: 405-749-6277 | |
Robert K Gelczer, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3433 Nw 56th St., Suite C-40, Oklahoma City, OK 73112 Phone: 405-945-4741 Fax: 888-972-5320 | |
Vikas Vij, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3433 Nw 56th St, Suite C-40, Oklahoma City, OK 73112 Phone: 405-945-4741 Fax: 888-972-5320 | |
William G Phillips, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 2224 Nw 50th St, Suite 276w, Oklahoma City, OK 73112 Phone: 405-858-2350 | |
Ronald Ray Magee, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5224 E I 240 Service Rd Ste 303, Oklahoma City, OK 73135 Phone: 405-608-3800 Fax: 405-628-6477 |